Loading clinical trials...
Loading clinical trials...
A Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0045 in Patients With Advanced Solid Tumors
Conditions
Interventions
HB0045 Drug Product
Locations
3
United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
The Gabrail Pharmacology Phase 1 Research Center LLC
Canton, Ohio, United States
UT M.D. Anderson Cancer Center
Houston, Texas, United States
Start Date
July 18, 2023
Primary Completion Date
September 19, 2025
Completion Date
March 19, 2026
Last Updated
October 23, 2023
NCT06625775
NCT05223608
NCT06051695
NCT06265727
NCT04665206
NCT05036226
Lead Sponsor
Shanghai Huaota Biopharmaceutical Co., Ltd.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions